What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Surgery
Gregory R. Pond spends much of his time researching Internal medicine, Surgery, Oncology, Clinical trial and Cancer.
His Internal medicine research is multidisciplinary, incorporating elements of Gastroenterology and Endocrinology.
The various areas that Gregory R. Pond examines in his Surgery study include Dexamethasone, Cohort study and Cohort.
His Oncology research incorporates elements of Survival rate, Adverse effect and Carcinoma.
The concepts of his Clinical trial study are interwoven with issues in Sorafenib, Informed consent, Retrospective cohort study, Patient participation and Performance status.
Gregory R. Pond interconnects Randomized controlled trial and Family medicine in the investigation of issues within Cancer.
His most cited work include:
- Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. (917 citations)
- Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study (858 citations)
- Predictors of infection in rheumatoid arthritis (436 citations)
What are the main themes of his work throughout his whole career to date?
Gregory R. Pond mostly deals with Internal medicine, Oncology, Surgery, Chemotherapy and Cancer.
His study in Breast cancer, Docetaxel, Prostate cancer, Clinical trial and Performance status falls within the category of Internal medicine.
His research in Docetaxel intersects with topics in Placebo, Mitoxantrone and Prednisone.
His Oncology research is multidisciplinary, incorporating perspectives in Randomized controlled trial, Salvage therapy, Proportional hazards model and Hazard ratio.
His Surgery study frequently links to adjacent areas such as Systemic therapy.
His Cancer research incorporates themes from Stage and Quality of life.
He most often published in these fields:
- Internal medicine (65.55%)
- Oncology (49.35%)
- Surgery (22.35%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (65.55%)
- Oncology (49.35%)
- Breast cancer (12.10%)
In recent papers he was focusing on the following fields of study:
His main research concerns Internal medicine, Oncology, Breast cancer, Cancer and Prostate cancer.
Cohort, Chemotherapy, Lung cancer, Quality of life and Disease are the primary areas of interest in his Internal medicine study.
His work on Overall survival as part of general Oncology research is often related to In patient, thus linking different fields of science.
The Breast cancer study combines topics in areas such as De-escalation, Clinical endpoint, Randomized controlled trial and Confidence interval.
Gregory R. Pond has researched Cancer in several fields, including Logistic regression, Retrospective cohort study and Multiple myeloma.
His Prostate cancer research integrates issues from Denosumab and Docetaxel.
Between 2017 and 2021, his most popular works were:
- Active Surveillance Magnetic Resonance Imaging Study (ASIST): Results of a Randomized Multicenter Prospective Trial (63 citations)
- Association of Metformin with Breast Cancer Incidence and Mortality in Patients with Type II Diabetes: A GRADE-Assessed Systematic Review and Meta-analysis. (50 citations)
- Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA (48 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
Internal medicine, Oncology, Breast cancer, Prostate cancer and Cancer are his primary areas of study.
Confidence interval, Cohort, Hazard ratio, Chemotherapy and Quality of life are subfields of Internal medicine in which his conducts study.
His Oncology study combines topics in areas such as Metastatic Urothelial Carcinoma and Atezolizumab.
His studies deal with areas such as Prospective cohort study, Cognition, Neuropsychology and Toxicity as well as Breast cancer.
His Prostate cancer research is multidisciplinary, relying on both Magnetic resonance imaging, Denosumab and Docetaxel.
Gregory R. Pond usually deals with Cancer and limits it to topics linked to Clinical endpoint and Trastuzumab, Metastatic breast cancer and CNS metastasis.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
